InvestorsHub Logo
Followers 27
Posts 5124
Boards Moderated 0
Alias Born 01/27/2014

Re: None

Monday, 07/26/2021 3:39:53 PM

Monday, July 26, 2021 3:39:53 PM

Post# of 1727
PH3 Topline presentation tomorrow...
The study met its primary endpoint and demonstrated that as a primary therapeutic intervention a single vaginal dose of DARE-BV1 achieved clinical cure rates of 70-81%.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DARE News